Skip to main content
. Author manuscript; available in PMC: 2014 Jul 21.
Published in final edited form as: Cell Metab. 2013 Nov 5;18(5):740–748. doi: 10.1016/j.cmet.2013.10.004

Fig. 3.

Fig. 3

Daily DNPME (5 mg/kg) reverses hyperglycemia, hypertriglyceridemia and hepatic steatosis in a low dose streptozotocin treated/3 day high fat fed rat model of type 2 diabetes and NAFLD. (A) Random plasma glucose concentrations during DNPME treatment. (B), (C) Fasting plasma glucose and TAG concentrations. (D), (E) Plasma glucose and insulin concentrations in an intraperitoneal glucose tolerance test. (F), (G) Liver and quadriceps TAG. For all panels, n=4–7 per group. In all cases, rats were fasted overnight before the study. Data are represented as mean ± S.E.M. In the panels comparing chow, vehicle-treated, and DNPME-treated rats, comparisons were by ANOVA. See also Fig. S3.